Total glucosides of peony ameliorates Sjögren's syndrome by affecting Th1/Th2 cytokine balance

Wu,Guolin; Wu,Nayuan; Li,Tianyi; Lu,Wenwen; Yu,Guoyou

doi:10.3892/etm.2016.3016

Total glucosides of peony ameliorates Sjögren's syndrome by affecting Th1/Th2 cytokine balance

Authors:
- Guolin Wu
- Nayuan Wu
- Tianyi Li
- Wenwen Lu
- Guoyou Yu
View Affiliations

Affiliations: Department of Chinese Traditional Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Function Institute of Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China
Published online on: January 22, 2016 https://doi.org/10.3892/etm.2016.3016
Pages: 1135-1141

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the molecular mechanisms underlying the effects of total glucosides of peony (TGP) in the treatment of Sjögren's syndrome (SS). A total of 40 mice with SS were evenly assigned into four groups, including: Control group; TGP group, receiving 1 mg TGP daily; hydroxychloroquine (HCQ) group, receiving 0.25 mg HCQ daily; and a combined group, receiving 1 mg TGP and 0.25 mg HCQ daily. After 8 weeks, quantitative polymerase chain reaction and an enzyme‑linked immunosorbent assay were used to detect the levels of interferon‑γ (IFN‑γ), interleukin‑4 (IL‑4), Fas and FasL in each group of mice. In addition, immunohistochemical analysis was used to determine the expression levels of IFN‑γ and IL‑4. IFN‑γ, IL‑4, Fas and FasL levels were significantly increased in the control group compared with the other three groups (P<0.05). Furthermore, the expression levels of these factors were reduced in the combined group in comparison with the HCQ group (P<0.05). The ratios of IFN‑γ to IL‑4 were decreased in the TGP and combined groups compared with the control group (P<0.05). The present results indicate that TGP ameliorates SS by affecting the Th1/Th2 cytokine balance and decreasing the expression levels of IFN‑γ, IL‑4, Fas and FasL. Therefore, TGP may represent a potential novel therapeutic agent for the treatment of SS.

View Figures

View References

1	Wang Y and Wang Y: Pharmacological study and clinical application of total glucosides of peony in autoimmune diseases. Zhe Jiang Zhong Yi Yao Da Xue Xue Bao. 2:240–241, 244. 2007.(In Chinese).
2	Zhang HF, Hou P and Xiao WG: Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjogren syndrome. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 27:596–598. 2007.(In Chinese).
3	Li X, Li X, Wang G, Qian L and Wang Z: Effectiveness and safety of total glucosides of peony in the treatment of patients with Sjogren syndrome. An Hui Yi Xue. 5:370–371. 2006.(In Chinese).
4	Wu GL, Pu XH, Yu GY and Li TY: Effects of total glucosides of peony on AQP-5 and its mRNA expression in submandibular glands of NOD mice with Sjogren's syndrome. Eur Rev Med Pharmacol Sci. 19:173–178. 2015.PubMed/NCBI
5	Carsons SE: Issues related to clinical trials of oral and biologic disease-modifying agents for Sjogren's syndrome. Rheum Dis Clin North Am. 34:1011–1023. 2008. View Article : Google Scholar : PubMed/NCBI
6	Nguyen CQ, Gao JH, Kim H, Saban DR, Cornelius JG and Peck AB: IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobese diabetic mouse. J Immunol. 179:382–390. 2007. View Article : Google Scholar : PubMed/NCBI
7	Munder M, Eichmann K and Modolell M: Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: Competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 160:5347–5354. 1998.PubMed/NCBI
8	Choi YJ, Saez B, Anders L, Hydbring P, Stefano J, Bacon NA, Cook C, Kalaszczynska I, Signoretti S, Young RA, Scadden DT, et al: D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev Cell. 30:255–267. 2014. View Article : Google Scholar : PubMed/NCBI
9	Elmansy H, Kotb A, Hammam O, Abdelraouf H, Salem H, Onsi M and Elleithy T: Prognostic impact of apoptosis marker Fas (CD95) and its ligand (FasL) on bladder cancer in Egypt: Study of the effect of schistosomiasis. Ecancermedicalscience. 6:2782012.PubMed/NCBI
10	Nakajima H and Oka T: Analysis of biochemical and biological functions of Fas-ligand (FasL) and Fas on activated T cells in allo-immune response. Transplant Proc. 29:1096–1100. 1997. View Article : Google Scholar : PubMed/NCBI
11	Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L and Greenberg PD: T cell mediated rejection of gene modified HIV specific cytotoxic T lymphocytes in HIV infected patients. Nat Med. 2:216–223. 1996. View Article : Google Scholar : PubMed/NCBI
12	Wu GL, Li TY, Lu WW, Yu GY and Fan YS: Effect of nourishing Yin, strengthening Qi and activating blood decoction on Fas/FasL in salivary glands of NOD mice with Sjogren's syndrome and their mRNA expression. Zhong Guo Zhong Yao Za Zhi. 38:4148–4151. 2013.(In Chinese).
13	Tzioufas AG, Kapsogeorgou EK and Moutsopoulo HM: Pathogenesis of Sjögren's syndrome: What we know and what we should learn. J Autoimmun. 39:4–8. 2012. View Article : Google Scholar : PubMed/NCBI
14	Jin L, Lloyd RV, Nassar A, Lappinga PJ, Sebo TJ, Swartz K, Seys AR, Erickson-Johnson MR, Roth CW, Evers BR, et al: HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR. Diagn Mol Pathol. 20:71–80. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kim SH, Lee MK, Lee KY, Sung SH, Kim J and Kim YC: Chemical constituents isolated from Paeonia lactiflora roots and their neuroprotective activity against oxidative stress in vitro. J Enzyme Inhib Med Chem. 24:1138–1140. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhou X, Ding J, Zhu M, Mou C, Wang H, Wang Y, He J, Chen R, Gao X and Yang Z: The effects on TNF-α and sICAM-1 in the adjuvant arthritis rat model by the total glucosides of peony. Xin Jiang Yi Ke Da Xue Xue Bao. 12:1677–1679. 2009.(In Chinese).
17	Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG and Bootsma H: Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum. 52:2740–2750. 2005. View Article : Google Scholar : PubMed/NCBI
18	Novljan Plešivčnik M, Rotar Z, Ambrožič A, Vidmar G and Tomšič M: Comparison of the performance of the different classification criteria for primary Sjögren's syndrome: A prospective cohort study. Clin Rheumatol. 33:1657–1664. 2014. View Article : Google Scholar : PubMed/NCBI
19	Shi H, Yu CQ, Xie LS, Wang ZJ, Zhang P and Zheng LY: Activation of TLR9-dependent p38MAPK pathway in the pathogenesis of primary Sjögren's syndrome in NOD/Ltj mouse. J Oral Pathol Med. 43:785–791. 2014. View Article : Google Scholar : PubMed/NCBI
20	Asamoto H, Akazawa Y, Tashiro S, Oishi M, Azuma T, Koide S, Sudo K, Yokota H and Tochino Y: Infiltration of lymphocytes in various organs of the NOD (non-obese diabetic) mouse. J Jpn Diabetes Soc. 27:775–781. 1984.
21	Wang D, Xue L, Yang Y, Hu J, Li G and Piao X: Temporal gene expression analysis of Sjögren's syndrome in C57BL/6.NOD-Aec1Aec2 mice based on microarray time-series data using an improved empirical Bayes approach. Mol Biol Rep. 41:5953–5960. 2014. View Article : Google Scholar : PubMed/NCBI
22	Vale DL: Recognition and management of Sjögren's syndrome: Strategies for the advanced practice nurse. Nurs Clin North Am. 35:267–278. 2000.PubMed/NCBI
23	Ramos-Casals M, Garcia-Carrasco M, Cervera R, Filella X, Trejo O, de la Red G, Gil V, Sánchez-Tapias JM, Font J and Ingelmo M: Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum. 32:56–63. 2002. View Article : Google Scholar : PubMed/NCBI
24	Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, Moutsopoulos HM and Thyphronitis G: The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol. 128:562–568. 2002. View Article : Google Scholar : PubMed/NCBI
25	Kang EH, Lee YJ, Hyon JY, Yun PY and Song YW: Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin Exp Rheumatol. 29:970–976. 2011.PubMed/NCBI
26	Mariette X: Pathophysiology of Sjogren's syndrome. Ann Med Interne (Paris). 154:157–168. 2003.(In French). PubMed/NCBI
27	Nagarkatti N: Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy. Cancer Immunol Immunother. 49:46–55. 2000. View Article : Google Scholar : PubMed/NCBI
28	Mor G, Gutierrez LS, Eliza M, Kahyaoglu F and Arici A: Fas-fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol. 40:89–94. 1998. View Article : Google Scholar : PubMed/NCBI
29	Saegusa K, Ishimaru N, Yanagi K, Mishima K, Arakaki R, Suda T, Saito I and Hayashi Y: Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjögren's syndrome. J Immunol. 169:1050–1057. 2002. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JC, Green D and Swain SL: Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med. 185:1837–1849. 1997. View Article : Google Scholar : PubMed/NCBI
31	Yung R, Kaplan M, Ray D, Schneider K, Mo RR, Johnson K and Richardson B: Autoreactive murine Th1 and Th2 cells kill syngeneic macrophages and induce autoantibodies. Lupus. 10:539–546. 2001. View Article : Google Scholar : PubMed/NCBI
32	Zhou Q, Bai T and Wu H: Expression of Th1/Th2 and Fas/FasL in the labial salivary gland of patients with Sjögren's syndrome and its significance. Xu Zhou Yi Xue Yuan Xue Bao. 28:28–30. 2008.(In Chinese).